2016 American Transplant Congress
Mycophenolate Mofetil Dose Reduction Are Associated with the Risk of Acute Rejection and Graft Failure After Renal Transplantation.
Background: Mycophenolate mofetil (MMF) is a highly effective immunosuppressive agent in transplant therapy. Although MMF is generally well tolerated, optimal therapy may be limited by…2016 American Transplant Congress
Therapeutically Equivalent Results to Caucasians in Black Kidney Transplant Recipients Using ASTAGRAF XL® Despite a Higher Degree of HLA Mismatch : A Post-Hoc Analysis of Phase III Data from Over 2000 Patients.
Astelleas Pharma Global Develepment, Northbrook, IL.
INTRO: When contemplating the use of a new immunosuppressant agent in kidney transplantation, measuring outcomes in potentially vulnerable populations is of paramount concern. As such,…2016 American Transplant Congress
Combination of Delayed Kidney Transplant (KT) and Better Quality Kidneys Offers Excellent Patient Survival in Combined Liver-Kidney Transplantation (CLKT).
Transplant Division, Department of Surgery, Indiana University, Indianapolis, IN.
Background: Despite prioritizing high MELD patients with the share-35 policy, patient survival in CLKT is relatively low. We previously showed the positive impact of delayed…2016 American Transplant Congress
Non-adherence is associated with increased risk of rejection and graft loss.
1Medicine, MUSC, Charleston, SC; 2Surgery, MUSC, Charleston, SC.
Non-adherence is common among kidney transplant recipients. However, data on the impact of appointment and medication non-adherence on kidney transplant outcomes are scarce. This study…2016 American Transplant Congress
Impact of Induction Therapy on Cardiovascular Events in Kidney Transplant Recipients.
1MUHC, Montreal, Canada; 2JHU, Baltimore.
Cardiovascular events (CVE) are one of leading causes of mortality in kidney transplant (KT) recipients and ATG use is reported as a risk factor. We…2016 American Transplant Congress
Association of Cytomegalovirus-Specific T Cell-Mediated Immunity with the Risk of CMV Infection Occurrence in Kidney Transplant Recipients.
Introduction CMV remains the significant cause of morbidity in transplant recipients. Despite universal prophylaxis, late CMV infection occurs in high proportion of kidney transplant recipients.…2016 American Transplant Congress
Financial Burdens and Coping Mechanisms of Living Kidney Donors.
1Yale U, New Haven; 2Northwestern U, Chicago; 3U Pennsylvania, Philadelphia.
BackgroundFinancial disincentives remain a major barrier to increasing rates of living kidney donation. A recent study found that 96% of living kidney donors (LKD) reported…2016 American Transplant Congress
Everolimus (EVR) versus Mycophenolate Sodium (MPS) for Recipients of Kidney Transplants from Expanded Criteria Donors (ECD) Receiving Anti-Thymocyte Globulin (r-ATG) and Tacrolimus (TAC).
Introduction: There is no standard of care immunosuppressive regimen for recipients of kidneys recovered from expanded criteria donors. Several centers use r-ATG induction due to…2016 American Transplant Congress
Tailored Rabbit Anti-Thymocyte Globulin Induction (rATG) Dosing for Kidney Transplantation.
1MMC, Portland, ME; 2MGMC, Augusta, ME.
Purpose: Although rATG is the most commonly used induction immunotherapy for kidney transplantation (KT), optimal dosing remains unknown. In order to minimize adverse effects and…2016 American Transplant Congress
Long-Term Death-Censored Graft Loss in the DeKAF Study.
The aim of the Deterioration of Kidney Allograft Function study (DeKAF) was to identify and assess the pathologies of troubled kidney grafts, that is, those…
- « Previous Page
- 1
- …
- 436
- 437
- 438
- 439
- 440
- …
- 531
- Next Page »